Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928562 | 0.87 | PLCG1 (0.34) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3548893 | 0.86 | POLB (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL5907432 | 0.86 | NPC1 (0.38) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3546268 | 0.86 | POLB (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3545934 | 0.86 | NPC1 (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3545937 | 0.86 | NPC1 (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL4793435 | 0.85 | HTT (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3553099 | 0.85 | HTT (0.32) | NPC1KMT2APOLBSMN1; SMN2PLCG1 | |
| SCHEMBL3551123 | 0.85 | NPC1 (0.31) | NPC1KMT2APLCG1RAB9APAX8 | |
| SCHEMBL3551120 | 0.85 | NPC1 (0.31) | NPC1KMT2APLCG1RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1988093-A1 | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | Wyeth a Corporation of the State of Delaware (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | NPC1 800/4885KMT2A 3127/4885POLB 338/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | NPC1 2612/4885KMT2A 803/4885POLB 886/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | NPC1 1707/4885KMT2A 1229/4885POLB 376/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | NPC1 1173/4885KMT2A 1332/4885POLB 453/4885 |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, PEPD, B2M | NPC1 2248/4885KMT2A 878/4885POLB 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.